|Day Low/High||163.00 / 166.61|
|52 Wk Low/High||130.09 / 181.81|
Obamacare? Trumpcare? These stocks don't care.
Here's a rundown of four technical setups that are showing solid trading potential.
Cramer shares his views on how the market had a slow, pre-Trump kind of day, and also discusses the next step in Adobe's tech surge.
Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected
Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial
Here's how to trade six of the most active names on the market this past week.
Wall Street ends with modest gains in a week in which the Federal Reserve decided to pull the trigger on an interest rate hike.
Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.
Stocks churn around the flatline to end the week as a selloff in health care counters gains seen elsewhere.
Fired former U.S. Attorney Preet Bharara was investigating stock trades made by Health and Human Services Secretary Tom Price, according to one report.
Today's session is reminiscent of a pre-Trump day.
Stocks rise on Friday even as a selloff in health care extends into its second day.
More downside is ahead for Amgen following Friday morning's huge breakdown gap.
Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer discusses Friday's most talked about stocks including Adobe Systems, Amgen, Canada Goose, Costco and Starbucks.
AveXis, Esperion Therapeutics, Medicines Co. and Amgen were among the biotech stock movers Friday morning.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer doesn't want to give up on Amgen.
Stocks creep lower on Friday as a selloff in health care extends into its second day.
Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
Oil and natural gas prices are on the downswing and one key measure seems to pointing that we could be nearing a pullback in the S&P.
Repatha costs $14,000 per year before discounts.
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent
Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.
Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.
Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.